Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website https://www.cardiologyres.org

Original Article

Volume 3, Number 4, August 2012, pages 158-163


Adjunctive Pharmacotherapy for Elective Direct Current Cardioversion in Patients With Atrial Fibrillation

Tables

Table 1. Baseline Characteristics
 
Patient CharacteristicsAll PatientsPatients with follow up
Mean(SD)Mean(SD)
ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; DCCV: Direct current cardioversion; DHP: Dihydropyridine; LA: Left atrium; LV: Left ventricle; N: Total number of patients; n: Number of patients with characteristic; SD: Standard deviation.
Mean age (years)66.7(± 10.44)66.82± 9.45
Mean LA diameter (cm)4.46(± 0.68)4.47± 0.74
n/N(%)n/N(%)
ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; DCCV: Direct current cardioversion; DHP: Dihydropyridine; LA: Left atrium; LV: Left ventricle; N: Total number of patients; n: Number of patients with characteristic; SD: Standard deviation.
Male98/130(75%)52/71(73%)
Previous DCCVs
  0107/130(82%)57/71(80%)
  120/130(15%)11/71(15%)
  22/130(2%)2/71(3%)
  31/130(1%)1/71(1%)
LV Systolic Impairment
  None102/130(79%)55/71(77%)
  Mild13/130(10%)9/71(13%)
  Moderate11/130(8%)5/71(7%)
  Severe4/130(3%)2/71(3%)
Medication Usagen/N(%)n/N(%)
ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; DCCV: Direct current cardioversion; DHP: Dihydropyridine; LA: Left atrium; LV: Left ventricle; N: Total number of patients; n: Number of patients with characteristic; SD: Standard deviation.
ACE inhibitors48/130(37%)25/71(35%)
ARBs16/130(12%)7/71(10%)
Amiodarone13/130(10%)7/71(10%)
Flecainide14/130(12%)11/71(15%)
Sotalol4/130(3%)1/71(1%)
Beta Blockers96/130(74%)53/71(75%)
Calcium Channel Blockers (non-DHP)12/130(9%)7/71
Calcium Channel Blockers (DHP)15/130(12%)5/71(7%)
Aldosterone antagonists8/130(6%)5/71(7%)
Digoxin17/130(13%)9/71(13%)
Outcomesn/N(%)n/N(%)
ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; DCCV: Direct current cardioversion; DHP: Dihydropyridine; LA: Left atrium; LV: Left ventricle; N: Total number of patients; n: Number of patients with characteristic; SD: Standard deviation.
Sinus Rhythm105/130(81%)22/71(31%)

 

Table 2. Multivariate Logistical Regression Analysis With Successful DCCV as the Dependent Variable
 
Independent variablesOdds RatioStandard ErrorP
DCCV: Direct current cardioversion; LA: Left atrium; AF: Atrial fibrillation; RAAS: Renin-angiotensin-aldosterone system.
RAAS inhibition-0.11828± 0.5000.8131
Age > 650.96359± 0.56300.0870
LA diameter-0.10351± 0.371180.7803
Flecainide0.07556± 1.033720.7803
Amiodarone-0.05231± 0.846420.9507
Sotalol-2.51290± 1.354840.0636
Beta Blocker0.39456± 0.537110.4626
Previous AF0.84147± 0.745840.2592

 

Table 3. Multivariate Logistical Regression Analysis With Maintenance of Sinus Rhythm at Follow up Following Successful DCCV as the Dependent Variable
 
Independent variablesOdds RatioStandard ErrorP
Boldface: Statistically significant; DCCV: Direct current cardioversion; LA: Left atrium; AF: Atrial fibrillation; RAAS: Renin-angiotensin-aldosterone system.
RAAS inhibition-0.03084± 0.383790.9360
Age > 65-0.15822± 0.393730.6878
LA diameter0.12418± 0.282570.6603
Flecainide2.14121± 0.931220.0215
Amiodarone0.09986± 0.618990.8718
Sotalol-2.04433± 1.39870.1439
Beta Blocker-0.11358± 0.443400.7978
Previous AF-0.44791± 0.543130.4096